SCHEMBL7808056

SCHEMBL7808056

Cn1c(-c2cccnc2)cc2ccccc21

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.67
CYP11B2 P19099 4/20 0.50
CYP2A6 P11509 4/20 0.50
ALDH1A1 P00352 3/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
CYP1A2 P05177 2/20 0.50
CYP3A4 P08684 2/20 0.50
HK1 P19367 1/20 0.50
HKDC1 Q2TB90 1/20 0.50
CYP2A13 Q16696 1/20 0.50
CYP2D6 P10635 1/20 0.50
HIF1A Q16665 1/20 0.50
HSD17B10 Q99714 1/20 0.50
IDO1 P14902 1/20 0.49
ADRA2A P08913 1/20 0.49
KCNH2 Q12809 1/20 0.48
AOC3 Q16853 1/20 0.48
KDM4E B2RXH2 1/20 0.47
MEN1 O00255 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7947787 0.83 CYP2A6 (0.49) KMT2ACYP11B2CYP2A6ALDH1A1CYP2C9
SCHEMBL24115004 0.82 AOC3 (0.53) KMT2ACYP11B2CYP2A6ALDH1A1CYP2C9
SCHEMBL1605704 0.82 AOC3 (0.56) KMT2ACYP11B2CYP2A6ALDH1A1CYP2C9
SCHEMBL12190142 0.82 CYP11B2 (0.58) KMT2ACYP11B2CYP2A6ALDH1A1CYP2C9
SCHEMBL29581156 0.81 KMT2A (1.00) KMT2AALDH1A1HSD17B10ADRA2AKDM4E
SCHEMBL214075 0.81 KMT2A (1.00) KMT2AALDH1A1HSD17B10ADRA2AKDM4E
SCHEMBL22005053 0.81 KMT2A (0.62) KMT2ACYP11B2ALDH1A1ADRA2AKDM4E
SCHEMBL27957076 0.81 KCNH2 (0.48) KMT2ACYP11B2CYP2A6ALDH1A1CYP2C9
SCHEMBL11035940 0.80 CYP11B1 (0.49) KMT2ACYP11B2CYP2A6ALDH1A1CYP2C9
SCHEMBL1605251 0.80 CYP11B2 (0.59) CYP11B2ALDH1A1CYP2C9CYP2C19CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200157076-A1 ACLY INHIBITORS AND USES THEREOF NIMBUS DISCOVERY, INC. 2020-05-21 US disclosed
EP-0949259-B1 N-HYDROXYUREA DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME NIKKEN CHEMICALS CO LTD (JP) 2001-06-20 EP disclosed
US-6184238-B1 ANTIALLERGENS, ANTIINFLAMMATORY AGENTS NIKKEN CHEMICALS CO., LTD. (JP) 2001-02-06 US disclosed
EP-0949259-A1 N-HYDROXYUREA DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME Nikken Chemicals Company, Limited (JP) 1999-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200157076-A1 ACLY INHIBITORS AND USES THEREOF ACLY, ATP5ME, ATP5MG KMT2A 1976/4885CYP11B2 2971/4885CYP2A6 2713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.